AKBA - 2 Small-Cap Stocks That Could Double Your Money
Generally speaking, small-cap growth stocks probably aren't the first place you'd look to invest in during a particularly turbulent market. Underscoring this point, small caps were hit far harder than their mid- and large-cap peers during the height of the COVID-19-induced sell-off in March.
However, the exceedingly sharp pullback among companies with market caps of less than $1 billion last month may have created some stellar buying opportunities for aggressive investors. Small-cap stocks have the best chance of posting the highest gains when the market goes into full-on recovery mode, after all.
Which small-cap growth stocks are the most compelling buys right now? If you have a high tolerance for risk and are on the hunt for super-charged growth opportunities, the little-known biotechs Akebia Therapeutics, Inc. (NASDAQ: AKBA) and Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) should definitely be on your radar this month. Wall Street, in fact, thinks both of these stocks could double in value over the next 12 months. Here's why.